In vitro and in vivo testing shows D-CAP-18 effectively reduces multidrug-resistant Pseudomonas aeruginosa infections, indicating its potential for treatment.
Key Points
D-CAP-18 demonstrated a significant 3 log decrease in infection compared to controls in vivo, underlining its therapeutic potential.
The MIC90 for D-CAP-18 was found to be 2 μg/mL, indicating strong antimicrobial activity against Pseudomonas aeruginosa strains.
A variety of tests, including time-kill kinetics and cytotoxicity assays, confirmed the effectiveness of CAP-18 derivatives against multidrug-resistant bacteria.
Observation of bacterial membrane damage via TEM suggests a unique mechanism of action for these peptides.